Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.61+0.28 (+1.02%)
Close on Nov 18, 2026Market cap $3.47BP/E 125.5Yield –
Arcutis Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Arcutis Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was $34.25M. For fiscal 2025 it was -$12.23M. The highest annual figure on record is -$12.23M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.23M | – |
| FY2024 | Dec 31, 2024 | -$128.40M | – |
| FY2023 | Dec 31, 2023 | -$241.10M | – |
| FY2022 | Dec 31, 2022 | -$301.63M | – |
| FY2021 | Dec 31, 2021 | -$206.53M | – |
| FY2020 | Dec 31, 2020 | -$136.65M | – |
| FY2019 | Dec 31, 2019 | -$43.13M | – |
| FY2018 | Dec 31, 2018 | -$19.74M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.09M | – |
| Q4 FY2025 | Dec 31, 2025 | $18.39M | – |
| Q3 FY2025 | Sep 30, 2025 | $8.53M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$39.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$50.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$61.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$76.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$68.42M | – |
| Q3 FY2022 | Sep 30, 2022 | -$104.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$65.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$62.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$71.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$57.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$42.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$36.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$38.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$35.63M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.95M | – |
See a number that looks wrong?